International Journal of Cancer Management

Published by: Kowsar

Prognostic Value of P63, Maspin, and MMP-2 Expression in Salivary Gland Adenoid Cystic Carcinoma

Nasim Taghavi 1 , * , Parisa Kardouni Khozestani 2 , Farzad Yazdani 3 and Alireza Akbarzadeh Baghban 4
Authors Information
1 Associate Professor, Dental Research Center, Oral and Maxillofacial Pathology Department, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Resident, Oral and Maxillofacial Pathology Department, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Associate Professor, Pathology Department, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
4 Ph.D in Biostatistics, Associate Professor , Proteomics Research Center, Department of Basic Science, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • International Journal of Cancer Management: February 2018, 11 (2); e7564
  • Published Online: February 7, 2018
  • Article Type: Research Article
  • Received: July 15, 2016
  • Revised: February 8, 2017
  • Accepted: January 27, 2018
  • DOI: 10.5812/ijcm.7564

To Cite: Taghavi N, Kardouni Khozestani P, Yazdani F, Akbarzadeh Baghban A. Prognostic Value of P63, Maspin, and MMP-2 Expression in Salivary Gland Adenoid Cystic Carcinoma, Int J Cancer Manag. 2018 ;11(2):e7564. doi: 10.5812/ijcm.7564.

Abstract
Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Zhou X, Huang S, Jiang L, Zhang S, Li W, Chen Z, et al. Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: Correlation with tumor progression and patient prognosis. Oncol Lett. 2014;7(5):1549-55. doi: 10.3892/ol.2014.1906. [PubMed: 24765174].
  • 2. Prasad ML, Barbacioru CC, Rawal YB, Husein O, Wen P. Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Mod Pathol. 2008;21(2):105-14. doi: 10.1038/modpathol.3800983. [PubMed: 18084258].
  • 3. Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression?. J Mammary Gland Biol Neoplasia. 2005;10(3):231-47. doi: 10.1007/s10911-005-9584-6. [PubMed: 16807803].
  • 4. Reis-Filho JS, Milanezi F, Silva P, Schmitt FC. Maspin expression in myoepithelial tumors of the breast. Pathol Res Pract. 2001;197(12):817-21. doi: 10.1078/0344-0338-00165. [PubMed: 11795829].
  • 5. Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol. 2003;201(4):562-72. doi: 10.1002/path.1483. [PubMed: 14648659].
  • 6. Sams RN, Gnepp DR. P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas. Head Neck Pathol. 2013;7(1):64-8. doi: 10.1007/s12105-012-0403-2. [PubMed: 23054955].
  • 7. Xia W, Lau YK, Hu MC, Li L, Johnston DA, Sheng S, et al. High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene. 2000;19(20):2398-403. doi: 10.1038/sj.onc.1203535. [PubMed: 10828881].
  • 8. Taghavi N, Sargolzaei S, Mashhadiabbas F, Akbarzadeh A, Kardouni P. Salivary Gland Tumors: A 15- year Report from Iran. Turk Patoloji Derg. 2016;32(1):35-9. doi: 10.5146/tjpath.2015.01336. [PubMed: 26832180].
  • 9. Speight PM, Barrett AW. Prognostic factors in malignant tumours of the salivary glands. Br J Oral Maxillofac Surg. 2009;47(8):587-93. doi: 10.1016/j.bjoms.2009.03.017. [PubMed: 19409681].
  • 10. Koul R, Dubey A, Binahmed A, Butler J, Cooke A, Abdoh A, et al. Prognostic factors depicting overall survival in lesser major (submandibular, sublingual) and minor salivary gland tumors. Turk J Cancer. 2008;38(4):159-66.
  • 11. Ramer N, Wu H, Sabo E, Ramer Y, Emanuel P, Orta L, et al. Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. Cancer. 2010;116(1):77-83. doi: 10.1002/cncr.24657. [PubMed: 19877114].
  • 12. Savera AT, Zarbo RJ. Defining the role of myoepithelium in salivary gland neoplasia. Adv Anat Pathol. 2004;11(2):69-85. [PubMed: 15090843].
  • 13. Pandey PR. Role of myoepithelial cells in breast tumor progression. Front Biosci. 2010;15(1):226. doi: 10.2741/3617.
  • 14. Boldrup L, Coates PJ, Laurell G, Nylander K. Differences in p63 expression in SCCHN tumours of different sub-sites within the oral cavity. Oral Oncol. 2011;47(9):861-5. doi: 10.1016/j.oraloncology.2011.07.002. [PubMed: 21802344].
  • 15. Edwards PC, Bhuiya T, Kelsch RD. Assessment of p63 expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and basal cell and canalicular adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(5):613-9. doi: 10.1016/S1079210403005742. [PubMed: 15153875].
  • 16. Rooper L, Sharma R, Bishop JA. Polymorphous Low Grade Adenocarcinoma has a Consistent p63+/p40− Immunophenotype that Helps Distinguish it from Adenoid Cystic Carcinoma and Cellular Pleomorphic Adenoma. Head Neck Pathol. 2014;9(1):79-84. doi: 10.1007/s12105-014-0554-4.
  • 17. Abd Raboh NM, Hakim SA. Diagnostic role of DOG1 and p63 immunohistochemistry in salivary gland carcinomas. Int J Clin Exp Pathol. 2015;8(8):9214-22. [PubMed: 26464669].
  • 18. Fonseca FP, de Andrade BA, Lopes MA, Pontes HA, Vargas PA, de Almeida OP. P63 expression in papillary cystadenoma and mucoepidermoid carcinoma of minor salivary glands. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(1):79-86. doi: 10.1016/j.oooo.2012.09.005. [PubMed: 23217538].
  • 19. Martins MT, Altemani A, Freitas L, Araujo VC. Maspin expression in carcinoma ex pleomorphic adenoma. J Clin Pathol. 2005;58(12):1311-4. doi: 10.1136/jcp.2004.025205. [PubMed: 16311353].
  • 20. Nakashima D, Uzawa K, Kasamatsu A, Koike H, Endo Y, Saito K, et al. Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int J Cancer. 2006;118(3):704-13. doi: 10.1002/ijc.21318. [PubMed: 16094606].
  • 21. Navarro Rde L, Martins MT, de Araujo VC. Maspin expression in normal and neoplastic salivary gland. J Oral Pathol Med. 2004;33(7):435-40. doi: 10.1111/j.1600-0714.2004.00220.x. [PubMed: 15250837].
  • 22. Ghazy SE, Helmy IM, Baghdadi HM. Maspin and MCM2 immunoprofiling in salivary gland carcinomas. Diagn Pathol. 2011;6:89. doi: 10.1186/1746-1596-6-89. [PubMed: 21943228].
  • 23. Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol. 2008;44(6):563-70. doi: 10.1016/j.oraloncology.2007.07.004. [PubMed: 17936671].
  • 24. Elahi M, Rakhshan V, Ghasemian NT, Moshref M. Prognostic value of transforming growth factor beta 1 [TGF-beta1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers. 2012;17(1):21-7. doi: 10.3109/1354750X.2011.635804. [PubMed: 22106837].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments